How to buy Zai Lab stock

Zai Lab Limited is a biotechnology business based in the US. Zai Lab shares (ZLAB) are listed on the NASDAQ and all prices are listed in US Dollars. Zai Lab employs 1,194 staff and has a trailing 12-month revenue of around 0.00.

Zai Lab share price

Use our graph to track the performance of ZLAB stocks over time.

Zai Lab shares at a glance

• Key figures

Information last updated 2021-03-10.

52-week range	$43.06 - $193.54
50-day moving average	$166.09
200-day moving average	$117.17
Wall St. target price	$174.24
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.12

Buy Zai Lab shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Zai Lab stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Zai Lab Limited by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zai Lab financials

Revenue TTM	$49 million
Gross profit TTM	$32.2 million
Return on assets TTM	-22.83%
Return on equity TTM	-36.74%
Profit margin	0%
Book value	$13.32
Market capitalisation	$11.1 billion

TTM: trailing 12 months

Shorting Zai Lab shares

There are currently 1.5 million Zai Lab shares held short by investors – that's known as Zai Lab's "short interest". This figure is 10.3% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Zai Lab shares can be evaluated.

Zai Lab's "short interest ratio" (SIR)

Zai Lab's "short interest ratio" (SIR) is the quantity of Zai Lab shares currently shorted divided by the average quantity of Zai Lab shares traded daily (recently around 351800.96153846). Zai Lab's SIR currently stands at 4.16. In other words for every 100,000 Zai Lab shares traded daily on the market, roughly 4160 shares are currently held short.

However Zai Lab's short interest can also be evaluated against the total number of Zai Lab shares, or, against the total number of tradable Zai Lab shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zai Lab's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Zai Lab shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Zai Lab shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zai Lab.

Find out more about how you can short Zai Lab stock.

Zai Lab share dividends

We're not expecting Zai Lab to pay a dividend over the next 12 months.

Zai Lab share price volatility

Over the last 12 months, Zai Lab's shares have ranged in value from as little as $43.06 up to $193.54. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zai Lab's is 1.1394. This would suggest that Zai Lab's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Zai Lab overview

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. The company offers Niraparib, an oral small molecule poly ADP ribose polymerase 1/2 inhibitor for the treatment of multiple solid tumors, including ovarian and other types of lung cancer; and Optune, a cancer therapy for the treatment of glioblastoma multiforme. It also develops Ripretinib, a switch control inhibitor for the treatment of KIT and/or PDGFRa-driven cancers, including gastrointestinal stromal tumors, systemic mastocytosis, and other cancers; REGN1979 for the treatment of diffuse large B-cell lymphoma and follicular lymphoma; Margetuximab an immune-optimized anti-HER2 monoclonal antibody for the treatment of breast and gastric cancers; and INCMGA0012, an investigational monoclonal antibody for the treatment of MSI-high endometrial cancer. In addition, the company develops Bemarituzumab, a humanized monoclonal antibody for the treatment of gastric and gastroesophageal cancers; Omadacycline, an antibiotic to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections; and Durlobactam for the treatment of acinetobacter baumannii bacterial infections. Zai Lab Limited has license and collaboration agreements with the TESARO Inc. ; Paratek Bermuda, Ltd. ; Five Prime Therapeutics, Inc.

Frequently asked questions

What percentage of Zai Lab is owned by insiders or institutions?
Currently 1.182% of Zai Lab shares are held by insiders and 70.218% by institutions. How many people work for Zai Lab?
Latest data suggests 1,194 work at Zai Lab. When does the fiscal year end for Zai Lab?
Zai Lab's fiscal year ends in December. Where is Zai Lab based?
Zai Lab's address is: Building 1, Jinchuang Plaza, Shanghai, China, 201210 What is Zai Lab's ISIN number?
Zai Lab's international securities identification number is: US98887Q1040 What is Zai Lab's CUSIP number?
Zai Lab's Committee on Uniform Securities Identification Procedures number is: 894789106